A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax™ ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727.
Meningococcal Serogroups A, C, W-135 and Y Vaccine
Infections, Meningococcal
Phase 3
An annotated case report form is not available for this study. A blank case report form will be provided.
October 2014